sulfamethoxazole has been researched along with Koch's Disease in 6 studies
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to determine the susceptibility of clinical isolates of multidrug-resistant (MDR) and non-MDR Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and trimethoprim/sulfamethoxazole over a 12 year period in Taiwan." | 7.78 | Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. ( Chen, YS; Huang, TS; Kunin, CM; Lee, SS; Syu, W; Yan, BS, 2012) |
| " However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients." | 5.43 | Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016) |
| "This study was designed to determine the susceptibility of clinical isolates of multidrug-resistant (MDR) and non-MDR Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and trimethoprim/sulfamethoxazole over a 12 year period in Taiwan." | 3.78 | Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. ( Chen, YS; Huang, TS; Kunin, CM; Lee, SS; Syu, W; Yan, BS, 2012) |
| " However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients." | 1.43 | Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ang, CW | 1 |
| Lee, BM | 1 |
| Jackson, CJ | 1 |
| Wang, Y | 1 |
| Franzblau, SG | 1 |
| Francisco, AF | 1 |
| Kelly, JM | 1 |
| Bernhardt, PV | 1 |
| Tan, L | 1 |
| West, NP | 1 |
| Sykes, ML | 1 |
| Hinton, AO | 1 |
| Bolisetti, R | 1 |
| Avery, VM | 1 |
| Cooper, MA | 1 |
| Blaskovich, MAT | 1 |
| Alsaad, N | 1 |
| Dijkstra, JA | 1 |
| Akkerman, OW | 1 |
| de Lange, WC | 1 |
| van Soolingen, D | 1 |
| Kosterink, JG | 1 |
| van der Werf, TS | 1 |
| Alffenaar, JW | 1 |
| Huang, TS | 1 |
| Kunin, CM | 1 |
| Yan, BS | 1 |
| Chen, YS | 1 |
| Lee, SS | 1 |
| Syu, W | 1 |
| SUGIMOTO, H | 1 |
| MIYAJIMA, T | 1 |
| Ludwig, G | 1 |
| Eykyn, SJ | 1 |
| Phillips, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis[NCT01832987] | Phase 2 | 12 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulfamethoxazole and Koch's Disease
| Article | Year |
|---|---|
Advances in antibiotics.
Topics: Adult; Anti-Bacterial Agents; Cephaloridine; Enterobacteriaceae Infections; Fusidic Acid; Gentamicin | 1969 |
5 other studies available for sulfamethoxazole and Koch's Disease
| Article | Year |
|---|---|
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
Topics: Animals; Chagas Disease; Disease Models, Animal; Mice; Mycobacterium tuberculosis; Nitroimidazoles; | 2022 |
Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tes | 2016 |
Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan.
Topics: Antitubercular Agents; Drug Interactions; Humans; Microbial Sensitivity Tests; Mycobacterium tubercu | 2012 |
[On results of the use of INH-sulfisomezole (especially in relation to the surgical treatment of pulmonary tuberculosis)].
Topics: Isoniazid; Sulfamethoxazole; Sulfanilamide; Sulfanilamides; Sulfonamides; Tuberculosis; Tuberculosis | 1961 |
[Epididymitis].
Topics: Adult; Diagnosis, Differential; Drug Combinations; Epididymitis; Gonorrhea; Hernia; Humans; Infant, | 1977 |